New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)

Informations projet

PAH-HOPE

N° de convention de subvention: 822258

DOI 10.3030/822258

Projet clôturé

Date de signature de la CE 17 Juillet 2018

Date de début 1 Octobre 2018

Date de fin 31 Mars 2021

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total € 3 570 000,00

Contribution de l’UE € 2 499 000,00

Coordonné par

ATXA THERAPEUTICS LTD
Ireland

Livrables

Open Research Data Pilot (1)

KOL Engagement, Communication & Dissemination

Engagement, communication & dissemination of recent development and progress on ATXA’s lead drug NTP42 including with key opinion leaders (KOLs) and other stakeholders of relevance to pulmonary arterial hypertension (PAH).

Publications

Peer reviewed articles (3)

Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Auteurs: Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Pedro Mendes-Ferreira, Rui Adão, Carmen Brás-Silva, B. Therese Kinsella
Publié dans: European Journal of Pharmacology, Numéro 889, 2020, Page(s) 173658, ISSN 0014-2999
Éditeur: Elsevier BV
DOI: 10.1016/j.ejphar.2020.173658

Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation

Auteurs: Eamon P. Mulvaney, Áine G. O'Sullivan, Sarah B. Eivers, Helen M. Reid, B. Therese Kinsella
Publié dans: Experimental and Molecular Pathology, Numéro 110, 2019, Page(s) 104277, ISSN 0014-4800
Éditeur: Academic Press
DOI: 10.1016/j.yexmp.2019.104277

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Auteurs: Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Annie Bouchard, Dany Salvail, B. Therese Kinsella
Publié dans: BMC Pulmonary Medicine, Numéro 20/1, 2020, ISSN 1471-2466
Éditeur: BioMed Central
DOI: 10.1186/s12890-020-1113-2

Conference proceedings (2)

NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension

Auteurs: T Kinsella, E Mulvaney, HM Reid
Publié dans: European Respiratory Journal, 2019, Page(s) PA5048
Éditeur: European Respiratory Society

Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Auteurs: T Kinsella, E Mulvaney, HM Reid
Publié dans: European Journal of Cardiology, Numéro 40, 2019, Page(s) P3670
Éditeur: Oxford Academic

Droits de propriété intellectuelle

Patent (1)

THROMBOXANE RECEPTOR ANTAGONISTS

Numéro de demande/publication: 16 739541
Date: 2016-06-13
Demandeur(s): ATXA THERAPEUTICS LTD